|
N.I. Volkova, S.O. Panenko, A.O. Golubeva
Is non-alcoholic fatty liver disease a consequence of obesity and a predictor of diabetes?
|
№12 / 2021
|
|
L.V. Tarasova (1, 2), Yu.V. Tsyganova (1), E.S. Sidyakina (1, 2)
Emphasis on infusion therapy with a polyionic succinate-methionine complex in the treatment of non-alcoholic fatty liver disease
|
№2 / 2021
|
|
S.A. Bulgakov
ESSENTIAL PHOSPHOLIPIDS IN THE TREATMENT OF HEPATIC DISORDERS
|
№s3 / 2018
|
|
V.G. Radchenko, P.V. Seliverstov, V.F. Ivanova, S.I. Sitkin
ALGORITHM OF TREATMENT OF NON-ALCOHOLIC FATTY OF LIVER DISEASE AND THE ROLE OF MITOCHONDRIAL DYSFUNCTION IN ITS DEVELOPMENT
|
№6 / 2017
|
|
A.F. Verbovoy, L.A. Sharonova, A.V. Pashentseva, I.A. Tsanava
INSULIN RESISTANCE SYNDROME IN THE CLINIC OF INTERNAL DISEASES
|
№5 / 2017
|
|
A.N. Kazyulin
POTENTIALS FOR THE EARLY PROPHYLAXIS OF PROGRESSION OF NONALCOHOLIC FATTY LIVER DISEASE IN THE PRACTICE OF CLINICISTS
|
№2 / 2017
|
|
E.N. Shirokova
NONALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK (LITERATURE REVIEW)
|
№2 / 2017
|
|
E.A. Mironova (1), O.E. Berezutskaya (2), N.L. Golovkina (2)
NONALCOHOLIC FATTY LIVER DISEASE: MODERN OPPORTUNITIES OF THERAPY
|
№15 / 2016
|
|
L.A. Zvenigorodskaya, M.V. Shinkin, T.V. Nilova, A.V. Petrakov, A.E. Lychkova
LIPID PEROXIDATION AND ACTIVITY OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN THE SERUM IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
|
№15 / 2016
|
|
I.G. Bakulin, E.V. Vinnytskaya, Yu.G. Sandler, V.A. Keiyan, S.V.Rodionova
ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH DIABETES MELLITUS
|
№2 / 2016
|
|
P.V. Seliverstov, E.M. Prikhodko, V.P. Dobritsa, V.G. Radchenko
SOME PROBLEMS OF DIAGNOSIS, TREATMENT AND PREVENTION OF NONALCOHOLIC FATTY LIVER DISEASE
|
№2 / 2015
|
|
V.V. Tsukanov, A.V. Vasyutin, Yu.L. Tonkikh, O.S. Amelchugova
THERAPY OF NONALCOHOLIC FATTY LIVER DISEASE. IS THERE A PLACE FOR HEPATOPROTECTORS?
|
№18 / 2014
|
Русский
